Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult men and women, aged 18 - 65~* Patients with mild to moderate essential hypertension: On both screening and Day -1 visit, mean sitting DBP should be ≥ 95mmHg and ≤ 114mmHg, and ΔDBP on Day -14 and Day -1 should be within 7 mmHg~* Patients who gave their consent to participate in this study and signed the written informed consent form~* Patients who have understood the study, and been judged to be cooperative and able to participate in the study until the study completion date~Exclusion Criteria:~1. Women of childbearing potential who have not received the hysterectomy or men who are not willing to use birth control measures.~2. Patients whose sitting DBP is \< 95mmHg or ≥ 115mmHg. Patients with severe hypertension whose SBP is ≥200mmHg~3. Patients with secondary hypertension~4. Patients with severe renal disease, gastrointestinal disorder, hematologic disorder, liver disease, etc. that can affect the absorption, distribution, metabolism and excretion of drugs~5. Patients with symptoms of orthostatic hypotension~6. Patients with severe insulin dependent diabetes or uncontrolled diabetes~7. Patients who suffered myocardial infarction or serious coronary arterial disease over the past 6 months or patients with clinically significant congestive heart failure or valvular heart disease~8. Patients with consumption disease, autoimmune disease, or connective tissue disease~9. Patients with the history of type B hepatitis or type C hepatitis~10. Patients with HIV infection or hepatitis~11. Patients with clinically significant abnormal laboratory test findings~12. Patients on any drug treatment that might affect the blood pressure~13. Patients with allergy or contraindication to angiotensin II-receptor antagonists~14. Patients with current or suspected alcohol addiction or history of drug abuse~15. Patients whose mean weight lies out of the range of -15% \~ +35%, based on the Modified Metropolitan Life Insurance table~16. Patients who are not eligible as subjects of the study, as determined by the principal investigator or a sub-investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, 3 tablets
- BR-A-657•K 20 mg group (Type: ACTIVE_COMPARATOR): Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
- BR-A-657•K 60 mg group (Type: ACTIVE_COMPARATOR): Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
- BR-A-657•K 180 mg group (Type: ACTIVE_COMPARATOR): Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).